Research location
New London
Connecticut, United States
Advertisement
Research activity in New London
Connecticut, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 45 trials and 46 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in New London
45 linked trials · page 1 of 1PRISM: Patient Experiences With PET Imaging in Prostate CancerNCT06523777 · 2024-07-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Nutrition and Prostate CancerNCT03532308 · 2018-11-21 · 1 site observation
TERMINATED
A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking ImpairmentNCT03567057 · 2018-07-18 · 1 site observation
COMPLETED
Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking ImpairmentNCT03436199 · 2018-03-29 · 1 site observation
COMPLETED
Addressing Dementia Via Agitation-Centered EvaluationNCT03226522 · 2017-07-13 · 1 site observation
COMPLETED
Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral NeuropathyNCT03219320 · 2017-06-27 · 1 site observation
COMPLETED
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)NCT02951598 · 2016-10-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research TrialsNCT02918539 · 2016-10-01 · 1 site observation
COMPLETED
Naltrexone/Bupropion Cardiovascular Outcomes StudyNCT02638129 · 2016-01-01 · 1 site observation
TERMINATED
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeNCT02446132 · 2015-11-13 · 1 site observation
TERMINATED
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeNCT02442765 · 2015-07-23 · 1 site observation
COMPLETED
SNORE (Smartphone Analyses of Nocturnal Obstruction by Respiratory Evaluation) SOUNDSNCT03288376 · 2015-02-13 · 1 site observation
COMPLETED
Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)NCT02245568 · 2014-08-01 · 1 site observation
TERMINATED
Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With DonepezilNCT02006641 · 2014-02-01 · 1 site observation
COMPLETED
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular EdemaNCT01994291 · 2013-11-01 · 1 site observation
TERMINATED
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's DiseaseNCT01723228 · 2012-11-01 · 1 site observation
COMPLETED
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's DiseaseNCT01689233 · 2012-10-01 · 1 site observation
COMPLETED
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.NCT01623596 · 2012-06-08 · 1 site observation
COMPLETED
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetesNCT01272219 · 2011-06-01 · 1 site observation
COMPLETED
Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular EdemaNCT01363440 · 2011-05-01 · 1 site observation
COMPLETED
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple SclerosisNCT01216072 · 2010-08-01 · 1 site observation
COMPLETED
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive DisorderNCT01153347 · 2010-06-01 · 1 site observation
COMPLETED
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and IncarceratedNCT01157351 · 2010-05-01 · 1 site observation
COMPLETED
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With NatalizumabNCT01070836 · 2010-03-01 · 1 site observation
COMPLETED
A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.NCT00754988 · 2008-10-01 · 1 site observation
COMPLETED
Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 DiabetesNCT00736879 · 2008-09-22 · 1 site observation
COMPLETED
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal WomenNCT00612742 · 2008-01-01 · 1 site observation
COMPLETED
A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) PatientsNCT00536471 · 2007-09-01 · 1 site observation
COMPLETED
Study Evaluating Bifeprunox in Patients With Schizophrenia.NCT00366327 · 2007-01-01 · 1 site observation
TERMINATED
Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary EndpointNCT00366704 · 2006-11-01 · 1 site observation
TERMINATED
Open Label Extension Study of BifeprunoxNCT00366171 · 2006-11-01 · 1 site observation
COMPLETED
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or NaproxenNCT00346216 · 2006-10-04 · 2 site observations
COMPLETED
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal WomenNCT00369343 · 2006-09-01 · 1 site observation
COMPLETED
Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.NCT00380224 · 2006-07-01 · 1 site observation
COMPLETED
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast CancerNCT00248170 · 2005-12-01 · 1 site observation
COMPLETED
Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)NCT00153803 · 2005-05-01 · 1 site observation
COMPLETED
Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung CancerNCT00112294 · 2004-12-01 · 1 site observation
COMPLETED
Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard TherapyNCT00095134 · 2004-10-01 · 1 site observation
COMPLETED
Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast CancerNCT00081796 · 2004-04-01 · 1 site observation
COMPLETED
Reduction in the Occurrence of Center-Involved Diabetic Macular EdemaNCT00090519 · 2004-02-01 · 1 site observation
COMPLETED
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant DepressionNCT00035321 · 2002-04-01 · 1 site observation
COMPLETED
Cognition in the Study of Tamoxifen and RaloxifeneNCT00687102 · 2001-10-01 · 1 site observation
COMPLETED
Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerNCT00054392 · 2001-09-01 · 1 site observation
WITHDRAWN
Iressa Expanded Access Program (EAP)NCT00034879 · 2000-08-01 · 1 site observation
COMPLETED
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal WomenNCT00003906 · 1999-05-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.